Recruiting

Preventing leukemia recurrence after stem cell transplant with maintenance medication

Plain-English translation of NCT05682755 on ClinicalTrials.gov ↗ · Source last updated January 2023 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing whether a medication called can help prevent acute myeloid leukemia from coming back after patients have received a stem cell transplant from a donor. Participants who have already had a stem cell transplant and achieved remission will take this medication by mouth for about 6 months. The goal is to see if the medication can reduce the risk of leukemia recurrence and manage side effects that sometimes happen after transplant.

Even when patients with high-risk acute myeloid leukemia achieve remission after a stem cell transplant, the disease can come back. Researchers hope this medication may help keep the leukemia from returning and potentially reduce harmful side effects that sometimes occur after transplant.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have recently received a donor stem cell transplant for acute myeloid leukemia and achieved complete remission
your transplanted cells have successfully started growing in your body (engrafted)
your overall health status is good enough to tolerate the treatment
you are able to commit to taking the medication daily for about 6 months and completing required medical appointments and tests

You likely don't qualify if…

you have serious organ damage or disease in your heart, liver, or kidneys
you have an active infection that is not responding to treatment
you currently have active graft-versus-host disease (a complication from the transplant)
you are pregnant, breastfeeding, or unable to use effective birth control
you have a known allergy to Chidamide or active hepatitis B or C infection

What participation looks like

Participants will take by mouth every day for approximately 180 days (about 6 months) after their stem cell transplant. During this time, you will have regular clinic visits and blood tests to monitor how well the treatment is working, check for any side effects, and watch for signs of leukemia recurrence. The study will track your health closely to evaluate whether the medication helps prevent the leukemia from returning.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(1 site)

China

West China Hospital of Sichuan University, Chengdu, Sichuan